Clinical trial aims to slow bone loss in dialysis patients

September 5, 2017

Many people with chronic kidney disease rely on dialysis to perform some of the functions of a healthy kidney, like removing waste, maintaining safe levels of chemicals in the body and helping to control blood pressure. However, individuals who use dialysis experience very high death rates—the mortality rate is approximately 25 percent each year, which is higher than many cancers. Around 70 percent of these deaths are related to cardiovascular events, such as heart attack and stroke.

Cardiovascular problems in are not exactly the same as in the general population. They are related to calcification in the arteries of the heart, in the brain, and throughout the body. Approximately 80 percent of dialysis patients experience calcification that progresses aggressively. This calcification is caused by . Although everyone's body is continuously breaking down old bone and creating new bone, patients on dialysis cannot absorb or excrete the calcium generated through this process. The excess load of calcium then deposits itself in the soft tissues of the body, leading to .

Bone loss itself is also a health risk for dialysis patients, because it leads to bone and joint pain as well as increased , which are also associated with high mortality.

At UK, a new clinical trial is trying to treat bone loss and thereby reduce or stop the progression of calcification in dialysis patients. The study, funded by the National Institutes of Health, offers participants an opportunity to be treated for their bone loss using one of two FDA-approved (non-experimental) medications. Both medications are already in use in the . One medication is prescribed to patients who don't make enough new bone, and the other is for patients who destroy too much bone. Simple blood tests will determine which medication is best for each study participant. Non-invasive measurements of bone loss and calcification will be taken to determine the benefits of the medications.

You might be eligible to participate in this study if you are on dialysis and are found to have osteoporosis (bone loss). There is no cost to participants, and you will be reimbursed for travel expenses.

To learn more, please contact Nedda Hughes or Tara Spach at (859) 619-5304, or you can contact them by email at nkhugh1@uky.edu and/or tara.l.spach@uky.edu. You may also find more information at UKClinicalResearch.com.

Explore further: Hormone and bone tests may be indicative of dialysis patients' heart health

Related Stories

Hormone and bone tests may be indicative of dialysis patients' heart health

April 2, 2015
Bone loss may be a sign of poor heart health in patients on dialysis, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Monitoring bone loss in dialysis patients ...

Drug may help prevent bone fractures in patients on dialysis

December 11, 2014
A drug that mimics calcium and lowers parathyroid levels may help prevent bone fractures in patients with kidney failure who are on dialysis, according to a study appearing in an upcoming issue of the Journal of the American ...

Weight loss surgery's effects on bone marrow fat and bone mass

August 9, 2017
Bone marrow fat is thought to regulate bone metabolism, and high levels of marrow fat are seen in states of low bone mass, severe underweight, and diabetes. In a study of obese women undergoing gastric bypass surgery, increases ...

Blood pressure medications reduce stroke and heart attack in peritoneal dialysis patients

June 14, 2016
Two classes of blood pressure medications, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are associated with a 16% lower risk of strokes, heart attacks and death in patients ...

Growth hormone reverses growth problems in children with kidney failure

April 4, 2013
Growth hormone therapy can help reverse growth problems in children with kidney failure, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). However, ...

Recommended for you

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

Research team unlocks secrets of Ebola

November 16, 2017
In a comprehensive and complex molecular study of blood samples from Ebola patients in Sierra Leone, published today (Nov. 16, 2017) in Cell Host and Microbe, a scientific team led by the University of Wisconsin-Madison has ...

Study raises possibility of naturally acquired immunity against Zika virus

November 16, 2017
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it.

A structural clue to attacking malaria's 'Achilles heel'

November 16, 2017
Researchers from The Scripps Research Institute (TSRI) and PATH's Malaria Vaccine Initiative (MVI) have shed light on how the human immune system recognizes the malaria parasite though investigation of antibodies generated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.